March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Comparison Of Intravitreal Bevacizumab Alone Or Combined With Triamcinolone Versus Triamcinolone In Diabetic Macular Edema: A Randomized Clinical Trial
Author Affiliations & Notes
  • Minchul Shin
    Ophthalmology, Chunchon Sacred Heart Hospital, Hallym University, Chuncheon-Si, Gangwon-Do, Republic of Korea
  • Hyokyoung Lee
    Ophthalmology, Chunchon Sacred Heart Hospital, Hallym University, Chuncheon-Si, Gangwon-Do, Republic of Korea
  • Jiwon Lim
    Ophthalmology, Chunchon Sacred Heart Hospital, Hallym University, Chuncheon-Si, Gangwon-Do, Republic of Korea
  • Footnotes
    Commercial Relationships  Minchul Shin, None; Hyokyoung Lee, None; Jiwon Lim, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 346. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Minchul Shin, Hyokyoung Lee, Jiwon Lim; Comparison Of Intravitreal Bevacizumab Alone Or Combined With Triamcinolone Versus Triamcinolone In Diabetic Macular Edema: A Randomized Clinical Trial. Invest. Ophthalmol. Vis. Sci. 2012;53(14):346.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To compare the effect of an intravitreal injection of bevacizumab alone (IVB) or combined with triamcinolone (IVB/IVT) versus triamcinolone (IVT) in patients with diabetic macular edema (DME).

Methods: : In this randomized three-arm clinical trial, eligible eyes were assigned randomly to one of the three study arms; the IVB group, two injections of 1.25 mg of bevacizumab with 6-week intervals; the IVB/IVT group, 1.25 mg of intravitreal bevacizumab with 2 mg of intravitreal triamcinolone; and the IVT group, 2 mg of intravitreal triamcinolone. The clinical course of best-corrected visual acuity and central macular thickness by optical coherence tomography was monitored for up to12 months after initial injection.

Results: : One hundred eleven eyes of 105 patients with DME completed 12 months of follow-up. The IVB/IVT group and the IVT group showed better visual acuity and reduced central macular thickness at 6 weeks and 3 months, compared with the IVB group (P=0.041, P=0.02 at 6 weeks; P=0.045, P=0.043 at 3 months, respectively). However, no significant difference in visual acuity and central macular thickness was observed between the three groups at 12 months (P=0.088, P=0.132, respectively). The frequency of retreatment was lower in the IVB/IVT and IVT groups during the12-month period (P < 0.001). No significant differences in visual acuity or central macular thickness were observed between the IVB/IVT and IVT groups during follow-up.

Conclusions: : IVB/IVT and IVT showed more pronounced effects during the earlier post-injection period. However, levels of visual acuity or central macular thickness at 12 months were comparable in the three study groups. No beneficial effect of the combination injection was observed.

Clinical Trial: : http://www.clinicaltrials.gov NCT01342159

Keywords: macula/fovea • vitreous • diabetic retinopathy 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×